Hepatocellular carcinoma: Molecular pathogenesis and therapeutic advances

Cucarull-Martínez, Blanca; Tutusaus, Anna; Rider, Patricia; Hernáez-Alsina, Tania; Cuño, Carlos; García de Frutos, Pablo; Colell, Anna; Marí, Montserrat; Morales, Albert

doi:http://dx.doi.org/10.3390/cancers14030621

Hepatocellular carcinoma: Molecular pathogenesis and therapeutic advances

License

Citation

Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular carcinoma: Molecular pathogenesis and therapeutic advances. Cancers (Basel). 2022 Jan 26;14(3):621. DOI: 10.3390/cancers14030621

Abstract

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to be a serious medical problem with poor prognosis, without major therapeutic improvement for years and increasing incidence. Fortunately, advances in systemic treatment options are finally arriving for HCC patients. After a decade of sorafenib as a standard therapy for advanced HCC, several tyrosine kinase inhibitors (TKIs), antiangiogenic antibodies, and immune checkpoint inhibitors have reached the clinic. Although infections by hepatitis B virus and hepatitis C virus remain principal factors for HCC development, the rise of non- alcoholic steatohepatitis from diabetes mellitus or metabolic syndrome is impeding HCC decline. Knowledge of specific molecular mechanisms, based on the etiology and the HCC microenvironment that influence tumor growth and immune control, will be crucial for physician decision-making among a variety of drugs to prescribe. In addition, markers of treatment efficacy are needed to speed the movement of patients towards other potentially effective treatments. Consequently, research to provide scientific data for the evidence-based management of liver cancer is guaranteed in the coming years and discussed here.